What is the appropriate ivermectin dose for a 48‑kilogram adult male?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ivermectin Dosing for 48 kg Adult Male

For a 48 kg adult male, administer 3 tablets of ivermectin 3 mg (total 9 mg) as a single oral dose on an empty stomach with water. 1

Indication-Specific Dosing

The appropriate ivermectin dose depends on the specific parasitic infection being treated:

Strongyloidiasis

  • Dose: 200 mcg/kg as a single oral dose 1
  • For 48 kg patient: 9.6 mg (approximately 3 tablets of 3 mg each)
  • According to FDA dosing guidelines, patients weighing 36-50 kg receive 3 tablets 1
  • Take on empty stomach with water to optimize absorption 1
  • Follow-up stool examinations should verify eradication; additional doses generally not necessary 1

Onchocerciasis

  • Dose: 150 mcg/kg as a single oral dose 1
  • For 48 kg patient: 7.2 mg (approximately 2-3 tablets)
  • FDA guidelines specify patients 45-64 kg receive 3 tablets 1
  • Retreatment may be considered at intervals as short as 3 months for individual patients 1
  • In mass distribution campaigns, 12-month intervals are most common 1

Loiasis (Alternative Treatment)

  • Dose range: 150-200 mcg/kg 2
  • Most commonly given as single dose, though some guidelines recommend daily dosing for up to 10 days in endemic settings 2
  • Critical safety consideration: Microfilarial load must be assessed before treatment
    • Safer when microfilarial count <8000 mf/ml 2
    • Risk of severe adverse reactions (including Mazzotti reaction) increases with higher parasite loads 2

Key Administration Points

Timing and Food Interactions:

  • Always administer on empty stomach with water 1
  • High-fat meals increase bioavailability approximately 2.5-fold, which may increase adverse effects 1

Pharmacokinetics:

  • Plasma half-life: approximately 18 hours 1
  • Peak concentrations occur approximately 4 hours post-dose 1
  • Metabolized primarily by CYP3A4 in the liver 1

Safety Considerations

Common Pitfalls to Avoid:

  • Never use in Loa loa co-infection without careful microfilarial assessment - risk of severe encephalopathy 2
  • Check for concomitant onchocerciasis in loiasis patients, as treatment algorithms differ 2
  • Avoid in patients with severe liver disease 3
  • Contraindicated in pregnancy and breastfeeding 3

Drug Interactions:

  • Monitor patients on CYP3A4 inhibitors or inducers 1
  • Avoid concurrent use with other drugs that may lower seizure threshold

Weight Threshold:

  • Minimum weight for treatment: 48 kg 3
  • Your patient is at the exact minimum threshold - ensure accurate weight measurement

Clinical Monitoring

After treatment, monitor for:

  • Adverse events (headache most common across all indications) 3
  • Treatment efficacy through appropriate follow-up testing (stool exams for strongyloidiasis, skin snips for onchocerciasis) 1
  • In loiasis: close observation for neurological symptoms if microfilarial load was elevated 2

The ivermectin dose calculation is straightforward for this 48 kg patient, falling precisely at the lower weight threshold in FDA dosing tables, making 3 tablets (9 mg total) the definitive dose for strongyloidiasis and the appropriate starting point for other indications 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.